Prevention of Stroke and Systemic Embolic Events in Patients With Atrial Fibrillation
Status:
Completed
Trial end date:
2008-06-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to provide dose-guiding information by assessing the safety
and tolerability of 4 different dosing regimens of an extended-release (ER) formulation of
AZD0837 compared with well-controlled, dose-adjusted Vitamin-K antagonists (VKA) (aiming for
an international normalized ratio (INR) 2.0 to 3.0) in patients with non-valvular atrial
fibrillation (AF) with one or more additional risk factors for stroke.